Ionis Pharmaceuticals Inc (NAS:IONS)
$ 35.91 -0.42 (-1.16%) Market Cap: 5.74 Bil Enterprise Value: 4.73 Bil PE Ratio: 0 PB Ratio: 8.65 GF Score: 40/100

Ionis Pharmaceuticals Inc Update on Clinical Studies Evaluating Tominersen (IONIS-HTT Rx) Transcript

Mar 22, 2021 / 09:00PM GMT
Release Date Price: $55.64 (+2.64%)
Operator

Good afternoon, and welcome to the Ionis Pharmaceuticals Tominersen Update Conference Call. As a reminder, this call is being recorded.

At this time, I would like to turn the call over to Mr. Wade Walke, Vice President, Investor Relations, to lead off the call. Please begin.

D. Wade Walke
Ionis Pharmaceuticals, Inc. - VP of IR

Thank you, Cole, and thank you, everyone, for joining us on today's call to discuss the tominersen development program. I encourage everyone to review the press release Ionis issued this afternoon, which can be found in the Investors section of the Ionis website.

Today's call will begin with brief opening remarks from Brett Monia, Chief Executive Officer; followed by Q&A during which Brett will be joined by Frank Bennett, Chief Scientific Officer; Eric Swayze, Executive Vice President of Research; and Eugene Schneider, Chief Clinical Development Officer.

Before we begin, I would like to remind everyone that we will be making forward-looking statements on today's call, which are based on our current

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot